Reference & Transfusion (R&T) Services

GRANULOCYTE PRODUCT ORDER & PHYSICIAN RELEASE FORM

Instructions:

- 1. Prior to completing this form: Call the Carter BloodCare (CBC) Medical Director On-Call at 817-482-9446.
- Once approval has been obtained from the CBC Medical Director, document all required information in the "Patient Information" and "Hospital Information" sections below.
- The ordering physician must read the statement below, sign and date the order/release form. Signature stamps are not acceptable. The order will be rejected without a handwritten signature from the ordering physician.
- Once all required fields of the form are completed, fax it to the R&T Services Department at 817-412-5749.
- Notify your hospital Blood Bank of the granulocyte order so they will be expecting this product from CBC. 5.
- Notify CBC Medical Director On-Call STAT if the order is to be canceled early. 6.

PATIENT INFORI	MATION										
Patient Name:			Med	lical Record	ID#:			Order Date) :		
Patient Weight:				Patient ABO	/Rh:			Date of Birth	1:		
Is Patient Taking Antifungal Medication?	between dose of medica					CMV Status:		☐ Positive ☐ Negative		Unknown	
Indication for Granulocytes:	☐ Bacterial sepsis with neutropenia ☐ Fungal sepsis with neutropenia ☐ Other:										
# of Days Product Needed:						NOTE: To guarantee granulocyte product yield, at least 48 hrs. must be allowed between order date and start date.					
HOSPITAL INFORMATION											
Ho	spital Name:	Component Reques			ponent Requested:		Granulocyte		Buffy Coat		
Hospital Blood Ba	nk Phone #:		Hospital Blood Bank Co			ntacted?	acted? Yes No		☐ No		
Ordering Phys	sician Name:	Ordering Physician Pho				ne Numb	er:				
Medical Necessity Documentation (Completed by Attending Physician): I certify that the product(s) indicated above is medically necessary for the treatment of this patient named above. I understand that the product(s) may be delivered immediately after collection and before infectious disease testing of the collected product(s) has been completed, and that this deviates from the regulations required by FDA (21 SFR 606.171[b]). However, the status of the patient's condition dictates that the product(s) indicated above is needed with sufficient urgency and the benefits of the product(s) being transfused outweigh the risk(s) involved. I understand that close monitoring of this patient for transfusion – associated adverse events should still occur per the transfusion facility's blood administration policy.											
Physician Signature:							Date:				
CARTER BLOODCARE R&T USE ONLY											
Received By CBC Tech Initials / ID#:	R&T	Daguma	Date/Time Received:	oue 9 Delive	m. 40	Sent to CBC MD On-Call?	☐ Ye	Date / Time:			
		Docume	iii Ploduct IS	sue a delive	יט נט	Distribution Below:					

Copyright © 2023 Carter BloodCare RTF205.13A

Version: 01 Effective Date: 02/01/2023